09885 YSB
- 5.770
- +0.080+1.41%
YSB News
The flu has boosted the performance of the pharmaceutical Sector, and YSB (09885) continues to repurchase shares, demonstrating confidence in its development.
YSB (09885) continuously published announcements on the Hong Kong Stock Exchange, stating that it will continue to repurchase a total of 0.32 million shares of the company on January 6, 7, and 8, 2025, for a total price of 1.8156 million Hong Kong dollars.
YSB (9885.HK) has been continuously repurchasing shares, and the Industry policies are Bullish for the company's long-term development.
On January 8, Gelonghui reported that YSB (9885.HK) announced on the Stock Exchange that it repurchased a total of 0.2 million shares on the market on January 6 and 7, at a total cost of 1.1375 million Hong Kong dollars. YSB stated in the announcement that the company believes the current stock price is below its intrinsic value and does not fully reflect its Business prospects. The company also indicated in the announcement that further repurchases may occur, demonstrating confidence in its Business outlook and prospects. Recently, the State Council General Office issued the "Opinions on Comprehensive Deepening the Reform of Pharmaceutical and Medical Instruments Regulation to Promote the High-Quality Development of the Pharmaceutical Industry," proposing 24 reform measures.
YSB Trustee Buys Back Shares for Incentive Scheme
YSB (09885): The trustee purchased 0.1 million shares according to the share incentive plan.
YSB (09885) announced that on January 6, 2025, according to the company and the REITs (trustee)...
Hong Kong stocks movement | YSB (09885) rose over 11% with Volume hitting a new high after completing the main delivery of the 100% equity acquisition project of "Yikuai Medicine."
YSB (09885) rose over 11%, with Volume hitting a record high. As of the report, it increased by 11.05%, priced at 6.43 HKD, with a turnover of 0.207 billion HKD.
Hong Kong stocks are moving丨YSB rose over 14%, Institutions are Bullish on the improvement in the Consumer Medical Sector's prosperity.
Gelonghui, December 16 | YSB (9885.HK) rose over 14%, reaching a high of 6.64 Hong Kong dollars, setting a new high since December. On the news front, Sinolink released a Research Report stating that the pharmaceutical industry will face continued pressure in 2024, but long-term demand remains stable, and there are reversal trends in policies, funding, and fundamentals, with the pharmaceutical track expected to achieve excess returns in 2025. Among them, in Medical Services and consumer healthcare, institutions are Bullish on the sector's improving prosperity under multiple policy drives. The establishment of the medical insurance fund budget system is expected to further standardize the turnover of expenses for pharmaceuticals and medical consumables, while also alleviating the upfront funding of medical institutions.
ysb (09885) issued 31.6786 million shares on November 26th.
Ysb (09885) issued an announcement that, according to the share purchase agreement, will operate under general authorization on November 26, 2024...
ysb (09885.HK) granted 1.86 million shares of bonus shares.
On November 6, Gronghui announced that ysb (09885.HK) issued 1.86 million bonus shares to the grantees under the stock incentive plan in 2024, accounting for approximately 0.29% of the total number of issued shares as of the date of this announcement. The reason for granting the bonus is to provide incentives for the grantees to strive for the success of the company and its affiliates, reward their unremitting efforts, and provide a way for them to benefit from the appreciation of shares by granting bonus shares.
YSB Set to Acquire Folding Space (Cayman) for 1.03 Billion Yuan, Changes Use of Proceeds From Global Offering
HK stocks surge | ysb (09885) opens over 5% higher, planning to acquire a pharmaceutical block with issued and outstanding shares totaling 1.035 billion yuan 100%
YSB (09885) opened more than 5% higher, as of the time of publication, it rose by 5.43%, closing at 7.76 Hong Kong dollars, with a turnover of 0.4982 million Hong Kong dollars.
YSB (09885) completed a full acquisition of a pharmaceutical company for 1.035 billion, accelerating the layout of its own brand business.
On October 15, 2024, YSB (09885) announced on the HKEX website that it has signed a trading agreement to acquire 100% equity of csi health care 100 index. The total consideration for the acquisition is RMB 1.035 billion, with a cash consideration of RMB 0.42 billion, and a stock consideration of RMB 0.615 billion.
YSB (09885.HK) cash plus new shares fully subscribed Hunan space folding, involving more than 1 billion RMB.
YSB (09885.HK) announced the acquisition of 100% equity of Hunan Spatial Fold, an independent third party, to acquire pharmaceutical supply chain, operation service platform, and related businesses. Through merging two customer networks, it aims to achieve mutual penetration and complementary advantages. The total consideration is 1.035 billion RMB, including 0.42 billion RMB in cash; and up to 56.2918 million shares issued as consideration shares, accounting for 8.74% of the expanded capital. The issue price is 12 RMB, a premium of 63.04% over the previous trading day (15th).
Each share of ysb has a premium of 63.04%, with a total acquisition of 1.035 billion in cash and new shares, fully acquiring "One Drug".
On October 15th, YSB (09885) announced on the HKEX that it has signed a trade agreement to acquire 100% of the shares of the csi health care 100 index, with a total consideration of RMB 1.035 billion, including a cash consideration of 0.42 billion yuan and a share consideration of 0.615 billion yuan. The share consideration part will issue new shares to the original shareholder of the csi health care 100 index at HKD 12 per share, with a premium of 63.04% over the closing price on the day of the signing of the acquisition agreement. This acquisition is a key step for YSB to deepen its industry layout, further enhancing its market competitiveness and profitability. The csi health care 100 index was established in 2019 and is a leading domestic
ysb (09885) intends to acquire Folding Space (Cayman) Ltd. with 1.035 billion yuan for 100% of the issued and outstanding share capital.
ysb (09885) issued an announcement, on October 15, 2024 (after the trading hours of the Stock Exchange), the company,...
YSB: 2024 Interim Report
Stock Connect market share abnormal statistics | September 9th
Statistics on the proportion of individual Hong Kong stock through the smart connect | September 6, 2024.
Pharmacist Help (09885) issued 1 million shares due to the exercise of stock rights.
Yao Shi Bang (09885) announced that, according to the share incentive plan adopted by the company on January 1, 2019...
As the profit potential gradually opens up, what did the pharmacist assistant (09885) do right?
On August 26, Pharmacist Help (09885) announced its latest semi-annual performance, not only achieving double-digit revenue growth, but also turning a profit for the first time. Net income exceeded 13 million yuan, turning positive for the first time from a significant loss.
Net income turning positive for the first time, how should we view Yaoshi Bang (09885.HK) going forward?
With the approaching of the Federal Reserve's interest rate cut window, highly interest rate-sensitive industries such as pharmaceuticals are having a positive market outlook. Many authoritative institutions have spoken out, pointing out that pharmaceutical stocks, due to their sensitive response to interest rate changes, are highly likely to stand out and become the darlings of the capital markets under the catalyst of interest rate cuts. Among them, many stocks with both cost-effectiveness and excellent potential are quietly nurturing rich investment opportunities, waiting for investors to discover. Recently, Pharmacist Help, China's largest digital comprehensive service platform for out-of-hospital pharmaceutical industry, released the performance data for the first half of 2024, with the company's revenue continuing to maintain double-digit growth.
Pharmacist (9885.HK) released interim results: revenue increased by 10.6% year-on-year, and net income increased by 30.3% after adjustment.
Pharmacist Assist today released its 2024 mid-term financial performance announcement.
No Data